Managing PIK3CA-Mutated HR+/HER2-Negative Advanced Breast Cancer in Clinical Practice

Dr. Jason Mouabbi introduces the discussion on managing PIK3CA-mutated HR-positive/HER2-negative advanced breast cancer in clinical practice, with a focus on treatment selection and practical adverse-event management.

Dr. Jason Mouabbi discusses the role of molecular testing in guiding treatment selection for patients with PIK3CA-mutated HR-positive/HER2-negative advanced breast cancer.

Dr. Jason Mouabbi presents a 59-year-old postmenopausal woman with PIK3CA-mutated HR-positive/HER2-negative advanced breast cancer who develops metastatic disease 8 months after completing adjuvant endocrine therapy.

Dr. Jason Mouabbi discusses strategies for assessing and managing the risk of treatment-related hyperglycemia before initiating therapy for patients with PIK3CA-mutated HR-positive/HER2-negative advanced breast cancer.

Dr. Jason Mouabbi reviews the treatment initiation and early glucose monitoring strategy for a patient with PIK3CA-mutated HR-positive/HER2-negative advanced breast cancer receiving inavolisib in combination with palbociclib and fulvestrant.

Dr. Jason Mouabbi discusses the approach to managing treatment-related hyperglycemia while maintaining cancer treatment for patients with PIK3CA-mutated HR-positive/HER2-negative advanced breast cancer.

Dr. Jason Mouabbi revisits the patient's Grade 2 hyperglycemia at week 6, when fasting glucose reaches 212 mg/dL.

Dr. Jason Mouabbi discusses additional adverse events that require attention when managing patients with PIK3CA-mutated HR-positive/HER2-negative advanced breast cancer receiving combination therapy.

Dr. Jason Mouabbi discusses how to approach adverse-event attribution when treating patients with PIK3CA-mutated HR-positive/HER2-negative advanced breast cancer with a multidrug regimen.

Dr. Jason Mouabbi returns to the patient case, noting improvement in the patient's osseous lesions and resolution of back pain after 3 months of treatment.

Dr. Jason Mouabbi discusses how available pathway-directed treatment approaches may be differentiated for patients with biomarker-selected HR-positive/HER2-negative advanced breast cancer, with consideration of treatment setting and toxicity profiles.

Dr. Jason Mouabbi discusses remaining unmet needs and practical considerations in the management of PIK3CA-mutated HR-positive/HER2-negative advanced breast cancer.